#cannabisaficionado

Industry Innovators

Peter Barsoom: Engineering Edibles & Elevating Expectations

Published

on

PHOTOS | 1906
Advertisement Back2Grow Advertisement

Continuing cannabis legalization has seen a boom in innovation and product development. One of the categories that has benefited the most is edibles. Gone are the days of freaking out from one too many weedy brownies. Modern edibles are healthier and more effective, in direct response to consumer demands. They are discreet, measured and the consumer experience and expectations can be precisely dialed in.

Peter Barsoom is the CEO of 1906, one of Colorado’s most successful and innovative edibles companies. 1906 has just released a groundbreaking product that marks a quantum leap for cannabis medicine: 1906 Drops that utilize pharma technology.

Cannabis Aficionado spoke to Barsoom about being first to market, his stance on social responsibility and cannabis entrepreneurialism.

Tell us about your journey through entrepreneurship and how you found your way to cannabis?

Prior to cannabis, I spent 20 years in finance in New York. The idea of getting into the cannabis market was really my wife’s idea. We came up to Colorado in mid-2014 and immediately realized how amazing the quality of the flower that was available to consumers. We wanted to create an edibles experience that was parallel to the amazing flower we had available to us — that’s when we started 1906.

Can you tell us a little about the name 1906?

1906 was the year the Wiley Act — also known as the Pure Food and Drug Act — was passed, which effectively started the prohibition of cannabis. Our mission is to do two things: bring awareness to the last 100 years of prohibition and also to bring cannabis back to its pre-prohibition status as a mainstream substance.

In your own words, what makes 1906 different from other edible companies on the market?

We focus on three things to attract a larger group of cannabis consumers for whom it could be an alternative for either alcohol or pharmaceuticals

Number one is great flavor. Because our product is food, it should taste like food and be healthy like the food we want to put in our bodies.

Two, it should deliver a specific effect. People use cannabis not just for getting high. People use it to help with sleep, give some relief from pain, help with anxiety, a boost of energy — there’s a specific reason why you or I use cannabis and it’s not just for “getting high.”

Third is that it’s fast-acting. Because I’m a New Yorker, I believe patience is a virtue and you shouldn’t have to wait for 60 minutes to 90 minutes for your edibles to kick in.

Can you go into detail on your patented ‘microencapsulation technology’ and the role it plays in your edibles?

Microencapsulation is the technology that we utilize that comes from the pharmaceutical world. Pharma knows how to make drugs get into your system faster. Or, in some cases, the extended release version.

We licensed the technology from a Canadian bioscience company, which is called a lipid microencapsulation. What that means is, by combining cannabis with the medium-chain fatty acid, it allows it to bypass or skip digestion, and get into your bloodstream faster.

Also, it avoids the degradation of the cannabinoids by your stomach acid, so you get more of the cannabinoids into your bloodstream.  You could almost think of it is as like a bullet train, where the cannabinoids are passengers that get into your bloodstream much faster and are protected more than the normal digestion.

Tell us about your exciting new product, the first medical cannabis pills on the market?

Yup, that’s correct. It really is very simple. At one level, it’s revolutionary. Another level, it’s as normal as anything else.

As Americans, we have four and a half billion prescriptions annually. Most of those come in what format? Pills that we swallow. The predominant way that Americans take medicine is in a pill form. It could be your pill for your cholesterol, your pill for sleep, your pill for anxiety. It was always odd to me that as cannabis is medicine, why wasn’t it available in the traditional medicinal format?

The second thing came from our consumers, which is that our consumers were asking for a vegan, gluten-free, portable, discreet way to take 1906. Maybe it’s somebody who can’t take chocolate because they have hypoglycemia, or they’re somebody who’s going out on a hike and can’t take chocolate pretzel because those will melt. There were a whole bunch of cases and demands from consumers for different products.

Pills are the way that we Americans consume our medicine. So, Drops was born from that work, bringing to the market a discreet, portable, vegan, gluten-free, something-you-can-swallow format.

Drops are the first cannabis pills on the market.

So, you’re reaching a new audience that doesn’t necessarily buy edibles or smoke flower or vape. But they’ll happily take a cannabis pill.

So true.  For a lot of people, it feels more accessible and acceptable in that format.

How’s the response been?

Phenomenal. We’ve had great, great feedback from the stores, and from our customers, so far. We have something that will resonate.

Where are they currently available?

Only in Colorado.

Any expansion plans?

Massachusetts, Michigan, Illinois and New Jersey will all be rolling out over 2020. Those are very exciting markets. There’s a great demand for these products in the new, young markets that are beginning to legalize. We can build the brand on the East Coast.

Can you tell us more about your GROW cannabis program?

We’ve developed a program called GROW Cannabis, which stands for Generate Real Opportunity for Working in Cannabis. This is for those individuals who’ve been negatively impacted by the War on Drugs. It was never a War on Drugs — it was a war on people. The people who’ve been negatively impacted, who are now out in society, their lives have been significantly damaged. The opportunities lost, the time that they spent in prison and so forth, is truly an injustice.

We think we have a responsibility to help those who’ve been incarcerated, to get back into society, through employment. This industry will create thousands of new jobs. Why not create a training program, so those people can gain real employment in this industry? So that’s what we’re doing. We’ll be launching next year in New Jersey, to get the program right and then we’ll be rolling it out in other areas.

As a New Yorker, what are your thoughts on the current situation in that state?

It’s hard. Every other state, besides Illinois, has done it through a ballot intuitive. It is very hard… it’s so political. I totally get it, the challenges they have. It takes a little while. It will happen. It takes like two years.

How can the cannabis industry, as a whole, be better?

I think it’s about remembering the community and how we got here. We got here because a lot of people were unfortunately incarcerated. That makes for a unique perspective. How we give back to the community? We’re creating a new industry, so we get to write new rules for it.

What trends do you predict for cannabis, going into the ‘Roaring Twenties’?

You know, I have… all I know is, it’s all being dictated by consumers. That’s where we’re seeing changes. The demand for legalizing, the demands for social use, the delivery, other options like that. If we’re looking into where consumers are, that’s what predicts what the future looks like.

With your experience, what do you see happening in the cannabis industry 1, 5 and 10 years from now?

I think in the next year, we’ll see something happen at a federal level — maybe not legalization, but maybe banking. In 10 years, we’ll start to see places where people can consume both cannabis and alcohol, in the same place. That will transform social use. It will transform how we gather… I think we will see beverages be a much larger way in which people consume cannabis.

What do you wish you knew when you started out cannabis entrepreneurship?

I wish knew how hard it was going to be. In retrospect, maybe I don’t wish? Maybe if I knew how hard it is, I might not have… but it is some of the most rewarding five years of my life.

Finally, what are three things people don’t know about what it takes to be a cannabis entrepreneur?

I think, number one, it will take more time and money than you can possibly predict. Number two: believe in what it is that you’re doing and listen to consumer demand. Keeping the consumer at the center of things, you’re more likely to be successful. Number three: I get a lot of advice from other folks in the business. This is one of the friendliest industries I’ve ever been a part of.

Industry Innovators

Auxly’s Cannabis Sales Rise as Last Year’s One-Time Gain Complicates the Profit Comparison

The Canadian cannabis producer’s revenue and operating cash figures improved, while its headline net-income comparison tells a different story.

Published

on

An aisle between warehouse racks filled with cardboard boxes

Auxly’s third-quarter cannabis results offer two headlines that need to be read together. Net revenue increased 24 percent from a year earlier to C$49.5 million, while reported net income declined. The difference does not mean the sales growth disappeared; it reflects, in part, a comparison with a prior-year quarter containing a substantial one-time gain.

The Canadian cannabis producer released its results November 12, 2026 for the three months ended September 30. Its accompanying financial statements and management discussion are dated November 11. Amounts here are Canadian dollars, avoiding a misleading comparison with U.S.-dollar figures reported by other cannabis companies.

Sales growth and the profit comparison

Auxly’s news release reports adjusted EBITDA of C$15.8 million, up 29 percent, and net income of C$13.6 million, compared with C$20.5 million a year earlier. Management notes that the 2025 comparison included a C$8.1 million after-tax gain related to the Imperial debenture settlement.

That creates a reason to examine the components of earnings rather than selecting whichever headline looks most dramatic. A settlement gain can raise reported profit without representing repeatable sales of cannabis. Conversely, removing selected items produces a different measure whose definition and reconciliation still need to be understood.

Adjusted EBITDA is not the same as net income, and neither is simply the amount of cash available for expansion. Auxly identifies adjusted EBITDA as a non-GAAP measure and directs readers to its reconciliation. The useful comparison is between consistently defined measures over time, with the excluded items visible.

The financial statements add a cash distinction

The interim statements report C$14.3 million of net cash provided by operating activities during the quarter. That differs from the C$14.8 million figure before working-capital changes highlighted in the announcement. Both can be accurate because they describe different stages of the cash-flow calculation.

Working capital includes movements in items such as receivables and inventory. A measure calculated before those movements helps isolate one aspect of performance, but it cannot answer every question about cash actually generated during the period. The statements provide the bridge between the two numbers.

At September 30, the statements show C$51.4 million in cash and cash equivalents. That is a balance at a particular date. It should not be confused with the quarter’s revenue, its net income or a promise that the entire balance will be spent on new production.

The statements also label the interim figures unaudited and explain that share and per-share amounts reflect the July 28 share consolidation. Those details matter when comparing old share counts or earnings per share, even though they do not change the basic story about cannabis sales.

Flower and pre-rolls remain central

The management discussion says dried flower and pre-roll products accounted for approximately 64 percent of quarterly net revenue, with the balance from the company’s other cannabis product categories. It attributes year-over-year sales growth to higher volumes across core products and improved flower pricing, partly offset by pressure on vape prices.

That is more informative for readers following the cannabis shelf than an undifferentiated growth percentage. Different formats can move in different directions at the same company. Higher total revenue does not establish that every product category gained pricing power or that every retailer saw the same demand.

The filing also describes the role of Auxly Leamington in cultivation and processing. An integrated production footprint can support supply, but its existence alone does not demonstrate consumer preference, product quality or a future sales result. Those claims require evidence beyond the size of a facility.

The previous quarter supplies context

Auxly’s August 13 second-quarter announcement reported C$45.8 million in net revenue and C$14.3 million in adjusted EBITDA. The third-quarter figures are higher than those earlier results, as well as higher than the year-earlier revenue and adjusted EBITDA comparisons. That is a useful check on the direction of the reported business.

Quarter-to-quarter changes are still different from a sustained trend. Product launches, customer ordering and seasonal patterns can affect individual periods. A single quarter does not establish the eventual return on a capital project or the success of an export strategy.

Our earlier coverage of Weedmaps’ tougher advertising quarter illustrated another part of the cannabis economy. The companies have different business models and reporting measures, so their results should not be treated as interchangeable signals for the whole industry.

For Auxly, the next useful tests are continued demand, cash generation after working-capital movements and the results of planned investments. The present filing supports a specific conclusion: cannabis revenue and several operating indicators improved, while the reported net-income comparison requires attention to last year’s exceptional items.

Illustrative warehouse stock photograph; not an Auxly facility or identified cannabis inventory. Photo: Russ Murray / Unsplash.

Continue Reading

Cannabis

Charlotte’s Web Reports Lower CBD Sales but a Narrower Quarterly Operating Loss

The hemp-derived CBD company’s latest results show why lower revenue and an improving quarterly loss can coexist—and why neither resolves the policy outlook.

Published

on

Empty amber glass bottles arranged on a light surface

Charlotte’s Web reported a difficult sales quarter for its hemp-derived CBD business while narrowing its operating loss. Revenue for the three months ended September 30, 2026 was US$9.4 million, down 18.3 percent from a year earlier. Its operating loss narrowed to US$3.7 million from US$5.3 million, showing why the direction of sales and the direction of a loss do not always match.

The company announced the results November 12 and filed its quarterly report with the U.S. Securities and Exchange Commission. The release attributes weaker revenue primarily to California restrictions that took effect in July, reduced promotional discounting and softer demand in parts of the hemp-wellness market. Those explanations are management’s account of the quarter, rather than an independent measurement of every factor affecting CBD shoppers.

Less revenue does not automatically mean a larger loss

The company’s earnings release reports quarterly gross profit of about US$4.4 million, compared with US$4.5 million a year earlier, even as sales fell. Gross margin improved to 46.9 percent from 38.9 percent. Selling, general and administrative expenses declined to US$8.1 million from US$9.7 million.

A percentage margin and a dollar profit measure answer different questions. A company can retain a larger share of each sales dollar while bringing in fewer dollars overall. Lower expenses can then narrow the operating loss without putting the business into operating profit. That is the distinction these results require.

The announcement also identifies an inventory reserve linked to simplifying the product range. Readers should therefore resist interpreting a single margin percentage as a permanent new baseline. Product mix, pricing, manufacturing costs and inventory adjustments can all affect the calculation.

The quarterly filing keeps the periods straight

The Form 10-Q records quarterly revenue more precisely at US$9.393 million and a net loss of US$3.458 million. These rounded to the US$9.4 million revenue and US$3.5 million net loss in the announcement. An operating loss and a net loss are different lines of the accounts, not conflicting reports of one number.

The nine-month picture is also distinct from the latest quarter. The release reports a US$20.7 million net loss for the first nine months, including noncash items associated with the earlier debenture conversion. It would be misleading to describe an improved third-quarter operating loss as proof that every year-to-date earnings measure improved.

The filing shows US$11.364 million of cash and cash equivalents at September 30. Cash on that date is a financial-position measure, rather than sales or profit earned during the quarter. Looking at the income statement and cash-flow statement together gives a fuller picture than treating a positive cash balance as evidence of profitability.

Hemp policy remains part of the business story

Cannabis policy is directly relevant to this CBD company because the legal definition of hemp determines which products can use that route to market. The Congressional Research Service’s October 28 legal sidebar explains that the federal delay does not move every element of the new definition to the same date. It distinguishes the treatment of certain cannabinoids not naturally produced by the plant from provisions delayed until December 11.

That distinction is useful beyond one company. A hemp-derived label does not settle a product’s future legal status, and a federal deadline does not automatically override a state’s separate rules. Consumers and businesses need to identify the applicable product definition, ingredients and jurisdiction.

Charlotte’s Web’s October 28 announcement said it planned to hold a corporate update after December 11 rather than a November earnings call, seeking greater policy clarity before discussing its outlook. That is a communications plan, not evidence that Congress will produce the outcome the company prefers.

Product access and medical evidence are separate

A financial report from a CBD business does not establish that a product treats a disease or is appropriate for a particular person. Sales trends describe commercial activity. They do not measure a clinical benefit, and a discussion of future healthcare distribution should not be mistaken for a new drug approval or a general reimbursement entitlement.

Our coverage of Willie Nelson’s hemp-policy appeal addresses the public debate over access. Charlotte’s Web’s results supply a different perspective: how a company says restrictions, pricing decisions and expenses are affecting its accounts. The two stories illuminate different parts of the same policy uncertainty.

The next meaningful business signals will include the durability of any sales recovery, spending levels and the details of the legal framework actually in force. For now, the results show a smaller quarterly operating loss alongside lower CBD revenue. They do not yet resolve whether the company can turn that improvement into sustained growth and profitability.

Illustrative empty-bottle stock photograph; not Charlotte’s Web packaging or identified CBD products. Photo: Kelly Sikkema / Unsplash.

Continue Reading

Industry Innovators

Portland Weighs Cannabis Pickup Windows and Licensing Payment Changes

Portland’s cannabis pickup-window and licensing proposal remains under review, with the city record listing a December 8 committee meeting.

Published

on

Portland waterfront buildings seen across the river

Portland is considering removing a city-code restriction on cannabis drive-through and walk-up sales, but the proposal has not become a new retail permission. The city’s record for Ordinance 2026-407 shows the November 10 City Life Committee item was continued, with December 8 listed as its next meeting date.

The proposal introduced by Mayor Keith Wilson combines two subjects: updating the language governing exterior sales windows and revising the way licensing-payment provisions appear in city code. For cannabis shoppers, the first is about how a purchase might be collected. For operators, the second concerns the timing and administration of license costs.

A retailer considering a physical alteration would still need to assess the property and any other applicable approvals. Removing one cannabis-specific sales restriction is not the same thing as approving a building project.

The window restriction is specific

Portland’s current marijuana licensing chapter bars sales from vendor carts, temporary structures, satellite locations and exterior openings such as drive-through facilities or walk-up windows. The proposed amendment would remove the exterior-opening language while retaining restrictions on those other kinds of sales locations.

That is narrower than allowing cannabis sales anywhere a customer can drive or walk. A licensed premises would still be a particular business location, subject to the rest of its applicable requirements. The change concerns a method of serving customers, not the disappearance of the licensing system.

City materials say the amendment would align Portland’s wording with Oregon rules that made on-site delivery a permanent option in September 2020, following temporary pandemic arrangements. That history helps explain why the debate is framed as an update to conflicting language rather than a brand-new statewide retail model.

Convenience does not mean on-site consumption

One important boundary remains in the proposed code exhibit: the provision against consumption on licensed premises is retained, with its existing narrow employee exception under Oregon law. A pickup window and a consumption lounge are different activities.

The same exhibit retains operating-hour and security requirements. Its redline shows a targeted deletion concerning sales openings, rather than an across-the-board removal of the rules governing retail premises. Reading the actual proposed changes is more informative than assuming that the phrase drive-through implies a completely different type of store.

For a customer, the practical questions would still include whether a specific retailer offers a service, how the order is handled and which rules apply. A citywide code amendment, if adopted, would not guarantee that every shop installs a window or changes its property layout.

The payment provisions affect operators differently

The ordinance also addresses the Deferred Payment Program for license fees. The city’s explanation says a 50% initial payment better supports collection and that the code should refer to the council-approved fee schedule rather than preserve outdated dollar amounts.

That is a distinction between the text of the code and the administration of a program. City materials say programmatic changes were communicated in June and July and implementation began in August. The proposal would codify practices already in place, according to the city, rather than introduce every payment change for the first time.

Operators evaluating the proposal therefore need both the amended text and the applicable fee schedule. A headline about pickup windows does not explain a business’s entire licensing bill, and an old fixed amount quoted from code may not describe current program administration.

Businesses are raising questions about cash flow

In KPTV’s November 10 reporting, Mikhala Armstrong described support for greater accessibility alongside concerns from cannabis operators about payment obligations and late fees. Those interviews add an important perspective to the city’s stated goal of improving administration.

The two views are not interchangeable. The city describes its intended program effects; individual operators describe how they believe the arrangements affect their businesses. A final assessment should distinguish those accounts from evidence about what happens after implementation.

Our coverage of Missouri’s interstate cannabis guidance concerned a separate jurisdiction, but illustrates a related point: legal cannabis markets remain governed by specific rules at different levels. A state allowance does not make every local detail irrelevant.

The next step is still a public decision

The city’s document history is the place to follow whether the committee advances or amends the proposal. As of this review, its status is continued, not adopted. Readers should check the updated agenda before relying on the December meeting listing or making plans to offer a new service.

The potential change is concrete: remove a particular restriction on how licensed cannabis stores serve customers and bring fee language into line with current administration. Whether that becomes the final city policy remains the question before Portland, rather than a decision already made.

Illustrative Portland waterfront photograph; not a dispensary or proposed pickup site. Photo: Meggyn Pomerleau / Unsplash.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.